We’re proud to be featured in UPMC Enterprises’ 2024 Year in Review, showcasing our continued progress towards our mission of transforming care for patients with central nervous system (CNS) disorders. This year, we achieved significant momentum with an additional $47 million raised in our Series B-1 Extension. These funds are propelling our development of cell-type specific therapies for CNS disorders, with a particular focus on advancing our Phase 3 clinical trial for solengepras (CVN424), a potentially first-in-class, oral, non-dopaminergic investigational therapy for Parkinson’s disease. Since joining the UPMC Enterprises portfolio in 2020, we’ve continued to build on our commitment to address other CNS challenges, working on potential treatments for Alzheimer’s disease, ALS, and frontotemporal dementia. We’re grateful for the support of UPMC Enterprises and our partners and their commitment and belief in our vision. https://lnkd.in/eJGsEHri
About us
Cerevance
- Website
-
http://www.cerevance.com
External link for Cerevance
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
One Marina Park Drive
Suite 1410
Boston, MA 02210, US
-
418 CAMBRIDGE SCIENCE PARK MILTON ROAD
CAMBRIDGE, CB4 0PZ, GB
Employees at Cerevance
-
Keith Page
-
Marina Lizio
Principal bioinformatician CNS and -Omics, based in Cambridge,UK.
-
Damon McCune, PhD, RDN, LD
Medical Affairs leader steering business excellence through innovation, empowerment, and strategy.
-
Matthias Kleinz
Life Science Investor and Executive Vice President at UPMC Enterprises
Updates
-
#ICYMI Last week, NeurologyLive featured the exciting milestone of dosing the first patient in our Phase 3 ARISE trial of solengepras (CVN424) for the potential treatment of Parkinson's disease. Check out the full article here to learn more about ARISE and our efforts to deliver transformative therapies to individuals with PD: https://lnkd.in/eyVzfyWt
Phase 3 ARISE Trial of Parkinson Therapy Solengepras Begins Dosing
neurologylive.com
-
We're very pleased to share that we have dosed the first patient in our pivotal Phase 3 ARISE trial of solengepras (CVN424) for the potential treatment of Parkinson's Disease. The trial will evaluate the efficacy of solengepras as an adjunctive therapy to levodopa and other background PD medications. Read the full press release to learn more about this important milestone and potentially transformative therapy for individuals with PD: https://lnkd.in/enxXFJWS
Cerevance Doses First Patient in Pivotal Phase 3 ARISE Trial of Solengepras for Treatment of Parkinson’s Disease
globenewswire.com
-
Today marks an exciting milestone for Cerevance with the release of positive data from our Phase 1 study of CVN293, a KCNK13 inhibitor, in healthy volunteers. The findings showed that CVN293 was well-tolerated for up to 14-days of continuous dosing and demonstrated robust brain penetration, supporting its potential advancement to a Phase 2 study. For more details on this important milestone, read the press release here: https://lnkd.in/eGYWeFmP
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
globenewswire.com
-
Alzheimer’s disease, the most common type of dementia, affects memory, thinking, and behavior. This National Alzheimer’s Awareness Month, join us in raising awareness about this disease. At Cerevance, we are focused on transforming the lives of those with Alzheimer’s through the development of cell-type specific treatments for CNS disorders.
-
Want to stay updated on the latest in #Parkinsons? Our Phase 2 #ClinicalTrial results for solengepras, featured in The Lancet's eClinicalMedicine, were published in an article by Parkinson's News Today. Read the full story here. https://lnkd.in/e4ximudK
Parkinson's off time lowered with solengepras as levodopa add-on...
https://parkinsonsnewstoday.com
-
We’re thrilled to announce the publication of our positive Phase 2 data from the clinical trial of solengepras for Parkinson’s disease in The Lancet's eClinicalMedicine. Check out the publication here: https://lnkd.in/eu4nxHZk
CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial
sciencedirect.com
-
Thrilled to welcome, Dr. Sarah Sheikh to our Board of Directors. Her deep expertise in #neuroscience will be an invaluable asset as we continue to advance our mission of transforming the standard of care for CNS disorders. https://shorturl.at/map16
Sarah Sheikh Joins Cerevance’s Board of Directors
globenewswire.com
-
Our CEO, Craig Thompson, recently shared his insights during a panel at the #FierceBiotechSummit, where he discussed the future of #neuroscience innovation. We’re grateful for the opportunity to be a part of this important discussion. Learn more: https://lnkd.in/egyxTVTT
-
We've achieved our second milestone in our research collaboration with Merck and are excited by the advancements we’ve made in identifying potential novel therapeutic targets for patients with Alzheimer’s disease. A huge thank you to our dedicated team and partners at Merck for their hard work and commitment to excellence. Read the press release here: https://lnkd.in/eFFxkMgH
Cerevance Achieves Second Milestone in Research Collaboration with Merck
globenewswire.com